Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Dachs1on Apr 23, 2016 2:57am
373 Views
Post# 24801852

RE:RE:Allergan back in acquiring mode.

RE:RE:Allergan back in acquiring mode.
Red5Luke wrote: Nice to see them back in buying mode.  

Hopefully they are so intrigue by Sirona's unique fluorination chemistry process they want to buy the whole company lock stock and barrel for some obscenely large amount!  Dare to dream - it's Friday! :)

GLTA.

 



Yes, see also the news from 6. April 2016:

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorder

-- Adds Selective Muscarinic Agonists Discovered and Developed by Heptares to Allergan's Leading CNS Pipeline --
-- Reinforces Allergan's Commitment to Development of Treatments for Alzheimer's Disease and Other Neurological Disorders --
-- Heptares Eligible to Receive Upfront, R&D and Milestone Payments, Plus Royalties --
 
https://www.allergan.com/NEWS/News/Thomson-Reuters/Allergan-and-Heptares-Announce-Global-R-D-and-Comm

Under the terms of the agreement, Heptares will receive an upfront payment of $125 million and is eligible to receive contingent milestone payments of up to approximately $665 million associated with the successful Phase 1, 2 and 3 clinical development and launch of the first three licensed compounds for multiple indications and up to approximately $2.5 billion associated with achieving certain annual sales thresholds during the several years following launch.

--------


If Allergan or not Allergan, it seems there is more movement comes in the cosmentic market. All majors companies want and/or need to grow to satisfy their shareholders. 

Have a nice weekend :)



Bullboard Posts